HOME >> MEDICINE >> NEWS
Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer

A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.

In today's New England Journal of Medicine, Sanford Markowitz, MD, PhD, writes an editorial accompanying research from Dr. Charles Fuchs' team at Harvard Medical School that lays out the hypothesized mechanism by which the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), also called COX-2 inhibitors, act to decrease the risk of developing colon cancer.

"The compelling evidence that chronic use of aspirin or certain NSAIDS can substantially lower the risk of colon cancer has important implications, especially because colon cancer is the second leading cause of cancer death," writes Dr. Markowitz, the Francis Wragg Ingalls Professor of Cancer Genetics at UHCMC and Case Western Reserve University School of Medicine.

In the Journal article, the Harvard researchers' findings demonstrated that two-thirds of colon cancers have high levels of expression of the COX-2 enzyme, which is blocked by aspirin. Individuals who regularly used aspirin over a course of several years demonstrated a 36% decrease in the risk of developing one of these high COX-2 expressing colon cancers. These results again demonstrated that drugs that block COX-2 can decrease the risk of colon cancer, and demonstrated that such drugs specifically target those individuals whose tumor development is encouraged by the action of the COX-2 enzyme.

Dr. Markowitz' accompanying editorial maps out those studies which will be required to determine the potential use of aspirin in prevention of colon cancer and to determine which individuals might benefit most from taking aspirin or aspirin-like drugs (NSAIDS) such as ibuprofen and Celebrex. Finally, the editorial outlines potential
'"/>

Contact: Alicia Reale
Alicia.Reale@UHhospitals.org
216-844-3825
University Hospitals of Cleveland
23-May-2007


Page: 1 2

Related medicine news :

1. Springer and the Royal Academy of Medicine of Ireland enter into publishing partnership
2. Ireland leads Europe for anti-tobacco policies while Luxembourg comes last
3. Coronary heart disease deaths in Ireland have halved in 15 years
4. Smoking ban is protecting bar workers in Ireland
5. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
6. Cancer research summaries
7. Cancer on the agenda of the Portuguese EU Council Presidency
8. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
9. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
10. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
11. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival

Post Your Comments:
(Date:12/22/2014)... Angeles, CA (PRWEB) December 22, 2014 ... reputable PALS, BLS and ACLS online certification provider, are ... http://www.acls-pals-bls.com . The updated site now features a ... easier than ever to use. , As a ... peoples’ information is now consolidated into a single page ...
(Date:12/22/2014)... U.S. and state health officials are investigating a listeria ... least four people and sickened 28 others in 10 ... prepackaged caramel apples until more information becomes available, the ... a news release. As of Dec. 18, a ... outbreak strains of the bacteria Listeria monocytogenes . ...
(Date:12/22/2014)... 22, 2014 Super Saturday, the last ... year as the busiest day in the 2014 holiday ... Grass Station had a steady pre-Christmas stream of customers, ... past Saturday. , “I definitely intend to take advantage…of ... Denver resident who was enjoying The Grass Station’s holiday ...
(Date:12/22/2014)... recognition of Veteran’s Day, Discount Labels contributed a portion ... that provides services to veterans and their families, free ... hundred acres in the hills of Southern Indiana, the ... hiking, horseback riding, 4-wheeling, skeet shooting, and much more. ... U.S. Service men and women, police officers, fire fighters ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 7,178 small ... bustle of Black Friday shopping and opted instead to ... marketing education company, for their 5th annual “Black Friday ... charged just $7 to attend the 5 hour online ... they promptly donated to support two Central Texas based ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... 22, 2014 TWi Biotechnology, Inc., today ... for AC-201, TWi Biotechnology,s lead drug candidate, from ... China for patent application numbered 201180018154.8.  ... salts, active metabolite for treatment of type II ... treatment using AC-201 for type II diabetes, and ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
Cached News: